News Roche abandons two Huntington's drug candidates Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.
News Bayer gets €3bn from Apollo for contraceptives unit stake Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptives products.
News Moderna's mResvia gets shot in the arm from EU contract A new EU procurement contract could give Moderna's RSV shot mResvia, which has struggled to gain traction in the market, a welcome boost.
News Keenova eyes Xiaflex as first drug for plantar fibromatosis Keenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet.
News GSK ends dementia alliance with Alector after setbacks GSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.
News NICE aims to cut funding for Amgen lung cancer drug Lumykras Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.